The company’s diabetes revenues grew 37.5% to $512 million in Q3. Abbott touted a number of regulatory wins for its FreeStyle Libre sensor-based continuous glucose monitoring system, including FDA approval of the 14-day system and CE Mark for its Libre 2 system.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,